Piramal Healthcare (UK) Ltd

Piramal Healthcare is an organization consisting of a network of global assets serving API and formulation process research, development & manufacturing at every phase of the drug lifecycle.

Piramal Healthcare (UK) Ltd

We are recognized for best-in-class services in the supply of APIs and formulations. This, combined with outstanding program management, differentiates both our quality and our ability to be competitive. Piramal Healthcare stands out as one of the few organizations that is able to progress a drug from proof-of-concept to the market stage, through commercialization, and ultimately manage the late lifecycle of the launched drug. This end-to-end support is made possible through our growing global network of manufacturing assets, R&D sites and novel technologies.

Piramal Healthcare consistently invests in the development of state-of-the-art facilities across North America, the United Kingdom and India. We provide our partners with flexibility and efficiency by offering customized projects across our network of services. Our FDA/MHRA-inspected sites have excelled in regulatory audits over the last few years as a direct result of our high standards for safety, quality and reliability when executing projects. With services extending across both APIs and formulations, we seamlessly integrate services – from clinical phase APIs and formulations to commercial phase APIs and finished dosage form supply – thereby reducing supplier complexity for our partners by providing more solutions within the same company.

We work with a number of biotech and virtual pharmaceutical companies to develop APIs from pre-clinical/phase I studies and formulations to commercial launch. Clinical-phase API and formulations development can be completed concurrently for quick project turnaround times. Additionally, projects can be moved to our other sites for late-phase drug cycle needs.

Our Grangemouth facility in Scotland offers synthesis and GMP manufacturing capabilities of highly potent substances (HPS) including small molecule cytotoxins, antibody drug conjugates and prostaglandins. Process R&D, analytical development and validation capabilities provide a wide range of services in the manufacture of high potency APIs. GMP suites are equipped with reactors for the supply of both clinical and commercial niche cytotoxic APIs.

Piramal HPS is organized with departments providing services related to:

  • Bioconjugation & Chemistry process development and optimization
  • Manufacturing of GMP material used in clinical studies
  • Analytical development, transfer and validation
  • Stability design, monitoring & testing
  • Quality assurance & regulatory support
  • Technology transfers & process validations

"Action, rooted in knowledge, translates into empowering care. We strive to achieve innovative and creative approaches." – Ajay Piramal, Chairman


Piramal Healthcare (UK) Ltd
Earls Road

01324 494100